The HemOnc Pulse

Dr. Osman on Identifying and Treating High-Risk MDS

On “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, met with Afaf Osman, MD, an Assistant Professor at the University of Utah Huntsman Cancer Center, to discuss how high-risk myelodysplastic syndromes (MDS) are distinct from lower-risk classifications and how to approach treatment.

Dr. Rami Komrokji on Trends in Real-World MDS Care

On “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, spoke with Rami Komrokji, MD, Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida, about the state of myelodysplastic syndromes (MDS) care. Moffitt Cancer Center is home to a large MDS database, with clinical information on nearly 6,000 patients, a trove of real-world MDS data.

Part One: The Question of MRD in CLL Therapy

Part one of this episode explores questions in measurable residual disease (MRD) and chronic lymphocytic leukemia (CLL) with Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health.
“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in various hematologic malignancies. 

‘The HemOnc Pulse’ Live: Unanswered Questions in T-Cell Lymphoma

At the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in T-cell lymphoma management. The panelists were Mehdi Hamadani, MD, a Professor of Internal Medicine at the Medical College of Wisconsin, Andrew Evens, DO, MBA, MSc, Deputy Director for Clinical Services at Rutgers Cancer Center, and Barbara Pro, MD, a Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.

‘The HemOnc Pulse’ Live 2024: Is it Time for New Endpoints in MPN?

Recorded at the first annual “HemOnc Pulse” Live meeting, this episode features a panel discussion on unanswered questions in myeloproliferative neoplasms (MPN) with Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center; Ruben Mesa, MD, of the Atrium Health cancer service line; Sanam Loghavi, MD, of the MD Anderson Cancer Center; and Olatoyosi Odenike, MD, of the University of Chicago Medicine.

Unpacking Bispecifics at ‘The HemOnc Pulse’ Live Meeting

“The HemOnc Pulse” was live for the first time in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in a range of hematologic malignancies. As part of the program, Michael Bishop MD, of the University of Chicago, and Aaron Goodman, MD, of the University of California, San Diego, were joined by Rafael Fonseca, MD, of the Mayo Clinic, to hold a panel on bispecific therapies and explore unanswered questions related to them.

'The HemOnc Pulse' Live: Unanswered Questions in Treating DLBCL

In this podcast episode covering the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in managing diffuse large B-cell lymphoma. The panelists included Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic; Jane Winter, MD, a Professor of Medicine in the Division of Hematology and Oncology at the Northwestern University Feinberg School of Medicine; and Alan Skarbnik, MD, Director of the Lymphoma and Chronic Lymphocytic Leukemia Program and of Experimental Therapeutics, Malignant Hematology at Novant Health.

‘The HemOnc Pulse’ Live 2024: Unanswered Questions in CML Treatment

Recorded at the first “HemOnc Pulse” Live meeting in Chicago, this podcast episode features a panel discussion on unanswered questions in chronic myeloid leukemia (CML) with Elias Jabbour, MD, a Professor of Medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the University of Miami Sylvester Comprehensive Cancer Center; and Sangeetha Venugopal, MD, MS, an Assistant Professor of Medicine at the Sylvester Comprehensive Cancer Center.

‘The HemOnc Pulse’ Live: What Are the Unanswered Questions in ALL?

Recorded at the first “HemOnc Pulse” annual meeting, this podcast episode features a panel discussion on unanswered questions in acute lymphoblastic leukemia (ALL) with Elias Jabbour, MD, a Professor of Medicine at the University of Texas MD Anderson Cancer Center; Shira Dinner, MD, an Associate Professor of Medicine (Hematology and Oncology) at Northwestern Medicine; Sanam Loghavi, MD, an Associate Professor of Pathology at MD Anderson Cancer Center; and Wendy Stock, MD, Co-Leader of the Clinical and Experimental Therapeutics research program at the University of Chicago Medicine Comprehensive Cancer Center.

Discussing the Role of MRD in CLL With Talal Hilal, MD

Dr. Hilal, of the Mayo Clinic, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss measurable residual disease (MRD) and the debates surrounding its use for response assessment in patients with chronic lymphocytic leukemia (CLL).